anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adults and Adolescents ≥12 Years Old

In a randomized, double-blind, placebo-controlled, cross-over study, 20 adults with mild-to-moderate asthma received single doses of XOPENEX Inhalation Solution (0.31 mg, 0.63 mg, and 1.25 mg) and racemic albuterol sulfate inhalation solution (2.5 mg). All doses of active treatment produced a significantly greater degree of bronchodilation (as measured by percent change from pre-dose mean FEV1) than placebo, and there were no significant differences between any of the active treatment arms. The bronchodilator responses to 1.25 mg of XOPENEX Inhalation Solution and 2.5 mg of racemic albuterol sulfate inhalation solution were clinically comparable over the 6-hour evaluation period, except for a slightly longer duration of action (>15% increase in FEV1 from baseline) after administration of 1.25 mg of XOPENEX Inhalation Solution. Systemic beta-adrenergic adverse effects were observed with all active doses and were generally dose-related for (R)-albuterol. XOPENEX Inhalation Solution at a dose of 1.25 mg produced a slightly higher rate of systemic beta-adrenergic adverse effects than the 2.5 mg dose of racemic albuterol sulfate inhalation solution. 

In a randomized, double-blind, placebo-controlled, cross-over study, 12 adults with mild-to-moderate asthma were challenged with inhaled methacholine chloride 20 and 180 minutes following administration of a single dose of 2.5 mg of racemic albuterol sulfate, 1.25 mg of XOPENEX, 1.25 mg of (S)-albuterol, or placebo using a Pari LC Jet™ nebulizer. Racemic albuterol sulfate, XOPENEX, and (S)-albuterol had a protective effect against methacholine-induced bronchoconstriction 20 minutes after administration, although the effect of (S)-albuterol was minimal. At 180 minutes after administration, the bronchoprotective effect of 1.25 mg of XOPENEX was comparable to that of 2.5 mg of racemic albuterol sulfate. At 180 minutes after administration, 1.25 mg of (S)-albuterol had no bronchoprotective effect. 

In a clinical study in adults with mild-to-moderate asthma, comparable efficacy (as measured by change from baseline FEV1) and safety (as measured by heart rate, blood pressure, ECG, serum potassium, and tremor) were demonstrated after a cumulative dose of 5 mg of XOPENEX Inhalation Solution (four consecutive doses of 1.25 mg administered every 30 minutes) and 10 mg of racemic albuterol sulfate inhalation solution (four consecutive doses of 2.5 mg administered every 30 minutes).
This will be a double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled, randomized (study drug assigned by chance), 2 way crossover ketamine challenge study (participants may receive different interventions sequentially during the trial) in 24 healthy male volunteers. For all participants, this study will consist of an eligibility screening examination, two 2-day treatment periods, separated by at least 1 week, and a follow-up examination about 7 days after last dose administration. The maximal study participation for each volunteer will be around 6 weeks. Apart from observing possible neural and vascular ketamine effects, the cerebral ketamine effects will be investigated by simultaneously performing fMRI/EEG during ketamine administration. These investigations will be done while volunteers rest as well as during cognitive testing (visual oddball task). Safety evaluations include continuous monitoring of vital signs and oxygen saturation. Due to the pharmacokinetic properties of ketamine the assessments will start after an intravenous ketamine bolus (drug given directly into the vein over a short period of time) followed by a 1 minute break. During the assessments there is a continuous intravenous (minimal) drug administration. Before the assessments start there will be an intravenous bolus of 0.1 mg/kg ketamine in 5 minutes time followed by a 1 minute break after which a continuous infusion will start of 0.015625 mg/kg/min ketamine. Since the plasma level elevates during the infusion the administered dose will be lowered by 10% every 10 minutes.
Photodynamic therapy (PDT) is a promising treatment against bacteria-caused infections. By producing large amounts of reactive oxygen species (ROS), PDT can effectively eliminate pathogenic bacteria, without causing drug resistance. However, excessive ROS may also impose an oxidative stress on surrounding tissues, resulting in local inflammation. To avoid this major drawback and limit pro-inflammation during PDT, this work prepared a supramolecular photosensitizer (TPP-CN/CP5) based on host-guest interactions between a cysteine-responsive cyano-tetraphenylporphyrin (TPP-CN) and a water-soluble carboxylatopillar[5]arene (CP5). TPP-CN/CP5 not only possesses excellent photodynamic antibacterial properties, but also shows good anti-inflammatory and cell protection capabilities. Under 660 nm light irradiation, TPP-CN/CP5 could rapidly produce abundant ROS for sterilization. After the PDT process, the addition of cysteine (Cys) triggers the release of H2 S from TPP-CN. H2 S then stops the induced inflammation by inhibiting the production of related inflammatory factors. Both in vitro and in vivo experiments show the excellent antibacterial effects and anti-inflammatory abilities of TPP-CN/CP5. These results will certainly promote the clinical application of PDT in the treatment of bacterial infectious diseases.
The invention discloses a physical constitution prediction method based on visible light and near infrared spectrum technologies, and belongs to the fields of visible light and near infrared spectrum technologies and traditional Chinese medicine physical constitution identification and diagnosis. The method comprises the steps of collecting spectral data of different parts of a user face, and determining the face position and the spectral data for modeling through spectral preprocessing and screening of the face spectral data position. According to the diagnosis of doctor, with the help of instrument, give the constitution prediction. And constructing a plurality of constitution prediction models according to the acquired spectral data and the corresponding constitution attributes. And in the prediction stage, the spectral data of the face part screened by the user is detected, preprocessing is carried out, a plurality of prediction model physique prediction judgments are carried out, and the final physique prediction result is obtained through comprehensive evaluation. The method is suitable for medical auxiliary prediction and daily physique prediction. The method improves the detection speed and the physique prediction accuracy, realizes the fusion of traditional Chinese medicine and various technologies such as physics, electromechanics, information and the like, and has obvious originality on the principle and the implementation scheme.
PURPOSE: To provide a topical pharmaceutical compsn. useful for treating inflammatory and profilerative dermatosis such as psoriasis and atopic dermatitis. CONSTITUTION: This pharmaceutical compsn. contains the effective amts. of the active compds. selected from a group consisting of pentoxyfylline, propentofylline and torbafylline and a pharmaceutically permissible topical carrier. Cyclosporin, methothrexate, tar derivatives, steroids, vitamin A (deriv.), vitamin D (deriv.), etc., the use of which is known in the topical treatment of the psoriasis and atopic dermatitis may be compounded with this compsn. The compsn. is applied in the form of lotion, cream, gel as well as in the form of a sprayable aerosol. The concn. of the active compd. of this time is preferably 0.5 to 5 wt.%.
Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
Mechanism of Action: 

Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene (LTB4, LTC4, LTD4, and LTE4) formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. 

Zileuton is an orally active inhibitor of ex vivo LTB4 formation in several species, including dogs, monkeys, rats, sheep, and rabbits. Zileuton inhibits arachidonic acid-induced ear edema in mice, neutrophil migration in mice in response to polyacrylamide gel, and eosinophil migration into the lungs of antigen-challenged sheep. 

Zileuton inhibits leukotriene-dependent smooth muscle contractions in vitro in guinea pig and human airways. The compound inhibits leukotriene-dependent bronchospasm in antigen and arachidonic acid-challenged guinea pigs. In antigen-challenged sheep, zileuton inhibits late-phase bronchoconstriction and airway hyperreactivity. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.
PROBLEM TO BE SOLVED: To obtain the subject preparation for external use for skin capable of manifesting effects on the prevention of the aging of the skin and maintenance, etc., of the elasticity of the skin by using an extract from a specific plant having effects on the suppression of the cross-linking of collagen or further, as desired, using an ultraviolet ray protectant in combination. SOLUTION: This antiaging preparation for external use for skin is obtained by using an extract separated from a plant belonging to the genus Lavandula of the family Labiatae as an active ingredient. For example, the species lavandula, angustifolia, lavender and lavandin are cited as the plant belonging to the genus Lavandula of the family Labiatae. Among the plants, an extract derived from that of a floral part is preferably used. The blending ratio of the extract is preferably 0.0001-10.0wt.%, especially preferably 0.001-1.0wt.%, based on the whole preparation for external use for the skin and expressed in terms of a dry substance.  Furthermore, 0.01-30wt.%, especially 0.1-20wt.% ultraviolet ray protectant (a long- wavelength ultraviolet ray protectant is especially preferred) is preferably blended in the system. 4-Methoxy-4-t-butyldibenzoylmethane, etc., are cited as the long-wavelength ultraviolet ray protectant.
Eligible subjects will be counselled and upon informed consent randomized for either medication or care as usual (i.e. no medication). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). In case of side effects Perindopril will be replaced by Valsartan 40 mg twice daily. A blood pressure below 120/80 mmHg is targeted. Blood pressure will be measured once per two weeks until the targeted blood pressure is achieved or until medication dosage has increased 4 times, corresponding Perindopril 10mg as maximum dosage or corresponding Valsartan 320mg (160 mg twice daily) as maximum dosage.
PURPOSE:To obtain a safe and hygienic beautifying agent of teeth, pleasantly applicable, providing natural luster and whiteness, comprising a solution of shellac resin in ethanol. CONSTITUTION:30-50wt.% shellac resin prepared by purifying secretions of scale insect is dissolved in 30-70wt.% ethanol and further mixed with 0-30wt.% water and stirred to give a uniform solution. The solution is optionally blended with 0.1-5wt.% fish scale foil into a dispersion and, if necessary, 0.001-0.5wt.% hydrophilic emulsifying agent is added to the water layer. The dispersion is properly mixed with a natural deodorant (e.g. extract of green tea), an antimicrobial agent (e.g. Japanese radish or extract of bamboo) or spice (e.g. lemon or orange essence), packed into a portable application container of knock type and prepared to give the objective substance. Teeth can be beautified any time any place readily by packing the substance into the container of knock type.
Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
Neuropathic pain (NP) is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system. At the trigeminal area where somatosensory nerves are often damaged during dental /maxillofacial interventions, post-operative orofacial neuropathic pain (OFNP) estimated treated prevalence/incidence rates were \~3-12%, with 83% of patients reporting that OFNP started with a dental treatment. Although OFNP is a burden for the society, and a major cause of chronic distress, disability and expenditure of medical resources, clinical trials that assess efficacy of its treatment are scarce. Until today, treatments of OFNP are extrapolated from those issued for neuropathic pain in other body sites. This clinical trial will be the first to evaluate the efficacy, safety, and tolerance of pregabalin in the treatment of OFNP. Based on the results obtained for neuropathic pain on non trigeminal areas, we expect to see positive results, and to provide evidence for effective management of OFNP with an anticonvulsant such as pregabalin.
PROBLEM TO BE SOLVED: To obtain an extracted liquid which is free from generation of discoloration and putrid smell and obtain further cosmetics to which the extract is added by extracting constituents at ordinary temperature from shotoku-seki a name of stone ground in powder by using ethyl alcohol aqueous solution of which a volume or volume % is specified. SOLUTION: A raw ore of sampled shotoku-seki is ground to a powdery state with a grinder. After adding 25-35 vol./vol.% of ethyl alcohol aqueous solution to this powder, it is left to stand at an ordinary temperature over one week to one month while it is stirring in a hermetically sealed container, and constituents of metal ions or the like contained in shotoku-seki are leached out in the ethyl alcohol aqueous solution. Then, the powder in the container is filtered, or supernatant in an upper part of the container is sampled, and an extract is obtained. The extract is added at a ratio of, for example, 0.1-5 wt./wt.% to cosmetics of cream, soap, toilet water or the like. Then, by medical effects of mineral ions or organic matter which are contained in the extract, metabolism function of the body is accelerated, or a hair root cell is activated.
Standard American Diet with meat source: lean pork. Diet adheres to 2015-2020 Guidelines for Americans.
Cerebral revascularization for the treatment of atherosclerotic steno-occlusive disease (ASOD) was found to have no benefit compared with medical treatment. However, there is also criticism that with sufficiently long-term follow-up, a crossover might emerge demonstrating the advantages of surgery. Therefore, we examined the long-term outcome of cerebral revascularization performed on patients with carefully selected ASOD at our center. Patients undergoing bypass surgery for non-moyamoya ischemic disease were retrospectively identified. The inclusion criteria were symptomatic ASOD with hemodynamic insufficiency, follow-up of more than 5 years, and stroke or surgical complications during follow-up. The clinical course and radiological findings were investigated. Poor outcomes were predicted using machine learning (ML) models, and Shapley additive explanation (SHAP) values and feature importance of each model were analyzed. A total of 109 patients were included from 2007 to 2018. The 30-day risk of any stroke or death was 6.4% (7/109). The risk of ipsilateral ischemic stroke during median follow-up of 116 months was 7.3% (8/109). The SHAP values showed that previously and empirically known stroke risk factors exert a relatively consistent effect on the prediction of models. The number of lesions with stenosis > 50% (odds ratio [OR] 5.77), age (OR 1.13), and coronary artery disease (OR 5.73) were consistent risk factors for poor outcome. We demonstrated an acceptable long-term outcome of cerebral revascularization surgery for patients with hemodynamically insufficient and symptomatic ASOD. Multicenter studies are encouraged to predict poor outcomes and suitable patients with large numbers of quantitative and qualitative data.
Clofarabine Injection may cause a cytokine release syndrome (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that may progress to the systemic inflammatory response syndrome (SIRS) with capillary leak syndrome and organ impairment which may be fatal. Monitor patients frequently for these conditions. In clinical trials, SIRS was reported in two patients (2%); capillary leak syndrome was reported in four patients (4%). Symptoms included rapid onset of respiratory distress, hypotension, pleural and pericardial effusion, and multiorgan failure. Close monitoring for this syndrome and early intervention may reduce the risk. Immediately discontinue Clofarabine Injection and provide appropriate supportive measures. The use of prophylactic steroids (e.g., 100 mg/m2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. Consider use of diuretics and/or albumin. After the patient is stabilized and organ function has returned to baseline, retreatment with Clofarabine Injection can be considered with a 25% dose reduction.
A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of  C. difficile  associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of  C. difficile  treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
In older adults dizziness is a common condition which is associated with repeated falls, fear of falling, depression, anxiety and ultimately loss of independence during activities of daily living. The main objective of this research was to compare the effects of balance training with and without Gaze Stabilization exercises on clinical outcomes in elderly patient with chronic dizziness.Total 64 participants after referral from neurologist were recruited in this study. These participants were randomly assigned into two groups i.e. Group A (Gaze group) and Group B (control group) with 32 participants in each group by sealed envelope method. Gaze group performed balance exercises with gaze stability exercises. Gaze stability exercises are further classified as adaptation and substitution exercises. Adaptation exercises support long term changes with a purpose of decreasing symptoms and maintain postural stability. On the other hand the substitution exercises improving central preprogrammed movement of eyes. Basically gaze stability exercises are defined as habituation exercises which reduce the symptoms of provoking stimulus by continuous exposure to it whereas, group B performed balance exercises with saccade eye exercises.Balance training includes both static and dynamic balance exercises, aimed to improved balance and postural stability with gradually increasing to challenging task. Exercises in balance training included a) single leg balance on firm surface b) heel stand c) marching on firm surface d) toe stand e) tandem walk f) forward and backward walking from normal base of support to weekly progression and training from eyes open to eye close from stable to unstable surface. Berg Balance Scale, Disability Handicapped inventory and Activity Specific Balance Confidence Scale were used to measure outcome variables.
Cases of overdose of up to 10 times the recommended bolus or continuous infusion dose of bivalirudin for injection have been reported in clinical trials and in postmarketing reports. A number of the reported overdoses were due to failure to adjust the infusion dose of bivalirudin in persons with renal dysfunction including persons on hemodialysis [see Dosage and Administration ( 2.2)] . Bleeding, as well as deaths due to hemorrhage, have been observed in some reports of overdose. In cases of suspected overdosage, discontinue bivalirudin for injection immediately and monitor the patient closely for signs of bleeding. There is no known antidote to bivalirudin. Bivalirudin is hemodialyzable [see Clinical Pharmacology ( 12.3)] .
FIELD: medicine. SUBSTANCE: method involves applying rectal electric stimulation with rectangular impulse packages of 6 ms duration and succession frequency period being 3 s long with current amplitude being equal to 8-12 mA and luminous action using infrared and red photodiode radiation during 8-10 min. Luminous action is carried out in pulsating mode synchronized with electric stimulation impulse frequency during the first 4-5 procedures. The following procedures are applied with 11-12 Hz frequency. The total course is 10-15 procedures long. EFFECT: enhanced effectiveness of treatment.
This trial consists of two arms. One arm is a non pre-treatment arm. Participants in this arm will receive placebo immediately after NSTEMI diagnosis and prior to the diagnostic coronary angiography. A 60 mg prasugrel loading dose will be given immediately after coronary angiography when proceeding to PCI. Subsequently, participants will receive daily maintenance doses of prasugrel until day 30. Participants who are greater than or equal to 75 years of age or who have a body weight less than 60 kilograms (kg) will receive 5 mg oral dose daily. All others will receive a 10 mg oral daily maintenance dose for 30 days.

The other arm is a pre-treatment arm where participants will receive a split loading dose regimen with 30 mg of prasugrel administered immediately after NSTEMI diagnosis and prior to diagnostic coronary angiography. The remainder of the loading dose (30 mg) will be administered when the participants are proceeding to PCI. Subsequently, participants will receive daily maintenance doses of prasugrel until day 30. Participants who are greater than or equal to 75 years of age or who have a body weight less than 60 kg will receive 5 mg oral dose daily. All others will receive a 10 mg oral daily maintenance dose for 30 days.